falsefalse

Redefining Allogeneic Transplants & Cellular Therapy: Key Takeaways from EBMT 2025 - Episode 14

Expert Perspectives: Orca-T Conditioning Regimens

, , ,

Panelists discuss how Orca-T may expand patient eligibility for allogeneic hematopoietic stem cell transplantation (alloHSCT) by including those typically considered high-risk for traditional transplant due to its lower toxicity and improved safety profile, potentially broadening the pool of eligible patients.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Summary for Physicians: Patient Eligibility for Orca-T vs Conventional AlloHSCT

    The discussion focused on how patient eligibility for Orca-T might differ from conventional alloHSCT, as follows:

    • Eligibility changes: Orca-T may expand eligibility criteria to include patients who are typically considered high-risk for traditional alloHSCT due to lower toxicity and improved safety profile.
    • Key differences: Compared with conventional alloHSCT, Orca-T may allow for a broader range of patients, including those with comorbidities or those previously excluded from standard regimens, to be eligible.

    In summary, Orca-T could potentially broaden the pool of eligible patients, offering treatment to those who may not be candidates for conventional alloHSCT.

    Nelli Bejanyan reports consulting or advisory role for CareDx, Medexus Pharmaceuticals, Orca Biosystems, AlloVir, TScan Therapeutics, and Pfizer; and research funding from CRISPR Therapeutics. Everett Meyer reports sponsored research from Orca Biosciences, Kyverna; and a scientific advisor role and equity holder for GigaMune, Indee, TRACT, Jura Biosciences.Caspian Oliai reports no relevant disclosures (investigator on the Orca T trial funded by Orca Biosciences). Arpita P. Gandhi reports roles with OncLive, MJH Life Sciences, OrcaBio (research), CareDx (Advisory Board). Amandeep Salhotra reports received funding from Rigel, Bristol Myers Squibb and Orca Biosciences; and speakers bureau for Incyte and Sanofi.

    x